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ABSTRACT  Pattern-recognition receptors (PRR) play a crucial role in the induction of the defense reactions of 
the immune system against pathogenic bacterial and viral infections. The activation of PRR by specific, highly 
conserved pathogen-associated molecular patterns (PAMPs) induces numerous immune reactions related both 
to innate and adaptive immunity. In addition to the well-studied Toll-like receptors, pathogens can be recog-
nized by the receptors belonging to the other PRR families; including NOD-like receptors (NLR). Stimulation of 
members of NOD-like receptors (NOD1, 2) and Toll-like receptors results in the activation of the transcriptional 
factor NF-kB  regulating gene expression in numerous molecules implicated in the development of proinflam-
matory reactions. As opposed to Toll-like receptors, the NF-kB-activating ability of NLRs has not been fully 
studied. In this work, we examine the ability of one member of the NLR family – NOD1 – to activate the main 
proinflammatory transcriptional factor NF-kB. We also compare the NF-kB-activating ability of NOD1 ligands 
of a different structure with TLR4,5 ligands in vitro and in vivo.
KEYWORDS pattern-recognition receptors, Toll-like receptors, NOD1-receptor, transcriptional factor NF-kB, 
peptidoglycan of gram-negative bacteria.
ABBREVIATIONS NF-kB – nuclear factor kappa-light-chain-enhancer of activated B cells); AP-1 – activator pro-
tein 1; TLR – Toll-like receptor; PAMPs pathogen-associated molecular patterns; DAMPs – damage-associated 
molecular patterns; PRR – pattern recognition receptor; TNF-α – tumor necrosis factor alpha; RT-PCR – reverse 
transcription polymerase chain reaction; IRF – interferon regulatory factor; NRL – NOD-like-receptor; RLR – 
RIG-like receptors; LPS – lipopolysaccharide.
INTRODUCTION
Until recently, both the mechanisms of recognition of 
infectious agents by macro-organism cells, as well as 
the molecular mechanisms of innate and adaptive im-
munity as a response to the developing infection, had 
not been subjected to adequate study.
An important step in the understanding of these 
mechanisms occurred twenty years ago, with the dis-
covery of the first representatives of the pattern recog-
nition receptors (PRR) of innate immunity:  TOLL-like 
receptors (TLR). Today, seven PRR families are known: 
Toll-like receptors, NOD (nucleotide-oligomerization 
domain)-like receptors (NLR), RIG-like receptors 
(RLR), lectin-like receptors, etc. [2]. Representatives of 
these families can recognize a set of highly conservative 
fragments of exogenous pathogen-associated molecular 
pattern (PAMP) molecules, as well as some endogenous 
damage-associated molecular pattern (DAMP) mole-
cules; each receptor having its specific set. The binding 
of intrinsic ligands with pattern-recognition receptors 
triggers intracellular signaling cascades,  resulting in 
the  activation of a number of transcriptional factors 
(AP-1, NF-kB, IRF 1, 3, 5, 7, etc.) which regulate the 
development of  particular immune responses.
NF-kB is the primary pro-inflammatory factor that 
regulates  the expression in a number of molecules 
which can participate in the development of reactions 
of both innate and adaptive immunity, such as the se-
cretion of pro-inflammatory cytokines and chemok-
ines, synthesis of antimicrobial peptides, induction of 
phagocytic activity of the microphages, dendritic cell 
maturation, etc. [3].
Toll-like receptors and the representatives of the 
fairly recently discovered subfamily of NOD-like re-
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ceptors, NOD1,2, belong to pattern-recognition recep-
tors, the activation of which results in an NF-kB induc-
tion.
Toll-like receptors are transmembrane proteins that 
are localized on the surface of the plasma membrane 
of cells and within intracellular compartments (endo-
somes). Such molecules of a different chemical nature, 
such as lipopolysaccharides (LPS), flagellin, bacterial 
lipopeptides, bacterial and viral DNA, etc., may serve 
as ligands of Toll-like receptors. Abundant data char-
acterizing the ability of TLR ligands to activate NF-kB 
both in vitro and in vivo has been collected [4]. The me-
diated NF-kB ability of TLR ligands to initiate different 
reactions of the immune system allows to use ligands as 
immediate protection agents against pathogens, mo-
lecular adjuvants, etc. [5–7].
Members of another PRR family – NOD receptors 
– are located directly in the cell cytoplasm and can rec-
ognize various molecules, which are fragments of pep-
tidoglycan of gram-positive and gram-negative bacte-
ria. It has been shown that NOD receptors participate 
in the recognition of bacteria capable of escaping the 
endosomal space and penetrating the cell cytoplasm 
and which can trigger specific immune responses [8]. In 
contrast to TLR ligands, the properties of NOD recep-
tor ligands, including their ability to activate NF-kB, 
have been studied considerably less.
This work focused on a comparative in vitro and in 
vivo analysis of the NF-kB-activating ability of ligands 
of one representative of NOD receptors, NOD1, as well 
as TLR 4 and 5 ligands. 
EXPERIMENTAL
Cell lines
The NF-kB-activating ability of ligands of the NOD1 
and Toll-like receptor 5 in vitro was studied using 
HEK293 cell lines (human embryonic kidney epithe-
lial cells) and HCT116 (human colon carcinoma cells) 
expressing NOD1 in humans. The cells were cultivated 
in a DMEM medium with 10 vol % of fetal bovine se-
rum (ref. number SV30160.03, Hyclone,United States); 
1 mg/ml glutamine (ref. number F032, PanEco, Rus-
sia); 50 U/ml penicillin; and 50 µg/ml streptomycin (ref. 
number A065, PanEco, Russia) was added at 37°С, in an 
atmosphere containing 5% CO2. The cells were seeded 
at a ratio of 1 : 6  on day 2, after the monolayer had 
been obtained.
Ligands of NOD1 and Toll-like receptors
The chemically synthesized NOD1 ligands, repre-
sented by samples of dipeptide  D-Glu-mDAP (iE-
DAP), tripeptide L-Ala-D-Glu-L-mDAP (Tri-DAP), 
the tripeptide covalently bound to a monosaccharide 
MurNAc-L-Ala-D-Glu-L-mDAP (M-Tri-DAP), and 
the molecule that contained the lauric acid fragment, 
Lauroyl-γ-D-Glu-D-mDAP (iE-DAP-C12), in addition 
to the minimal recognition sequence, were purchased 
from Invivogen, United States (ref. numbers: tlrl-dap, 
tlrl-tdap, tlrl-c12dap). Ligand ТLR4 – LPS   – was pur-
chased from Sigma-Aldrich, United States (ref. number 
L3024). Ligand TLR5 –flagellin was prepared according 
to the procedure described in [9].
Extraction and Purification of Molecule  GlcNAc-
MurNAc-L-Ala-D-Glu-L-mDAP – the fragment of 
peptridoglycane of Neisseria meningitidis serogroup 
В – NOD1 receptor ligand
Primary cultivation of N. meningitidis (wild-type strain 
591 belonging to serogroup B was isolated from the cer-
ebrospinal fluid of a meningitis patient in Moscow in 
1985. Phenotype: B : NT : P1.1,2) was carried out at a 
temperature of 37°C in the presence of 5% CO2 in the 
Thayer Martin medium (ref. number M413, Himedia, 
India). In order to add selective properties to the me-
dium, a set of antibiotics V.C.N.T. Supplement (ref. 
number FD024, Himedia, India) was introduced. The 
preparative growth of the bacterium was carried out 
in a Brain Heart Infusion broth (ref. number 211059, 
Difco, United States) with 10 vol % of equine serum at 
37°C added upon rocking (160 oscillations/min). The lig-
and of a NOD1 receptor was extracted and chromato-
graphically purified according to the earlier published 
procedure [10], which include the preliminary thermal 
inactivation of bacteria at 65°C for 1 h and phenol-
chloroform extraction upon heating and mixing of the 
phenol–water mixture at 70°C for 30 min. The aque-
ous phase containing peptidoglycan fragments was 
subjected to tangential-flow ultra filtration (Millipore, 
United Stated) through a filter with a pore diameter of 
30 kDa. The filtrate was purified via three sequential 
methods of reversed-phase high-performance liquid 
chromatography (HPLC) on a Bio-alliance 2796 chro-
matograph (Waters, United States). The first two stag-
es of the purification procedure were carried out using 
a Symmetry С18 Column with a particle diameter of 
5 µm, 4.6 × 75 mm (Waters, United States).  During the 
final stage of purification, a Synergi Hygro-RP 80 Å 
column (particle diameter of 4 µm, 250 × 3 mm (Phe-
nomenex, United States)) was used.
Chromatographic separation of the compounds was 
performed on a spectrophotometric detector 2487 
(Waters, United States, λ 205, 260, and 280 nm). A 
Q-STAR Elite mass spectrometer with Turbo Spray 
and Nano Spray ion spray ionization sources (Applied 
Biosystems/MDS SCIEX, United States) was used as 
a detector at the final (third) stage of purification. The 
resulting sample containing a mass spectrometrically RESEARCH ARTICLES
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pure substance underwent mass spectrometric analy-
sis in order to determine the primary structure of the 
molecule under study. At the first stage of analysis, 
the accurate molecular mass of the substance, equal to 
850.353 Da, was determined.  The molecules of the sub-
stance subjected to study were then fragmented in an 
ion spray ionization source for further determination of 
the sequence of amino acids comprising the molecule, 
using Protein Pilot software (Applied Biosystems, Unit-
ed States). The non-protein part of the molecule was 
identified by pseudo-MS3 (studying the products of 
the secondary fragmentation of ions obtained by pre-
decomposition of an analyzed molecule in the ionization 
source). The final brutto formula of the analyzed mol-
ecule was determined by a study of the decomposition 
paths of the decomposition of its ion.
The comparative analysis of the fragmentation 
spectra of different control substances (including N-
acetylglucosamine) and the analyzed compound under 
identical conditions made it possible to identify the pri-
mary structure of the molecule: GlcNAc-MurNAc-L-
Ala-D-Glu-L-mDAP.
 The same experiment was performed on the sam-
ples of the bacterial culture medium (negative control) 
in order to verify the results obtained.  Furthermore, 
the biological activity of the sample containing the sub-
stance under study, i.e., its ability to activate NF-kB in 
cells via the Toll-independent mechanism, was meas-
ured following each chromatographic stage of purifi-
cation.
Measurement of β-galactosidase activity
Twenty-four hours after the study samples were 
added to the cells, the culture medium was removed 
and the cell lysis buffer with β-galactosidase substrate 
(1 mM MgCl2; 0.25 M Tris-HCl, pH 7.4; 0.02% NP40; 2 g/l 
o-nitrophenyl-β-D-galactopyranoside (ref. number 
102473, MP Biomedicals, United States)) was added. 
The level of activity of β-galactosidase was determined 
spectrophotometrically (414 nm) on the basis of sub-
strate (o-nitrophenyl-β-D-galactopyranoside) conver-
sion into the colored product o-nitrophenol.
Determination of bioluminescence intensity in 
HCT116 and HEK293 line cells containing the luci-
ferase reporter gene under expression control of the 
NF-kB-dependent element
At the preliminary stage, HCT116 and HEK293 line 
cells were infected with a lentiviral vector containing 
the luciferase reporter gene under expression control 
of the NF-kB-dependent promoter. A day before the 
bioluminescence was to be determined, the cells were 
seeded into a 96-well plate with a confluence of 2 × 104 
per well.  The following day, the samples of PRR lig-
ands were added to the cells, and after 8 more h, the 
lysis buffer containing luciferin Bright-Glo™ Luciferase 
Assay System (ref. number E2620, Promega, United 
States) was also added. The buffer volume (100 µl) was 
equal to the volume of the culture medium. The level of 
activity of luciferase was determined on the basis of the 
fluorescence intensity by means of a Wallac 1420 plate 
reader (Perkin Elmer, United States).
Determination of bioluminescence intensity in the 
samples of organ homogenates of BalB/C transgenic 
mice
PRR ligands (LPS or iE-DAP-C12) were intramus-
cularly introduced into BalB/C transgenic mice con-
taining the luciferase gene, under control of the NF-
kB-dependent promoter, after which the organs were 
collected at intervals of 1, 3, and 5 h. The organs were 
homogenized in a Reporter Lysis 5x Buffer (ref. number 
E3971, Promega, United States) with inhibitors of cell 
proteases added. The level of activity of the transcrip-
tional factor NF-kB in the samples of mouse organ ho-
mogenates  was determined by the bioluminescence 
intensity in the samples, normalized with respect to 
protein content (10 mg) using a Wallac 1420 plate read-
er (Perkin Elmer, United States).
Determination of expression of NOD1 receptor by RT-
PCR
The total RNA from HCT116 and HEK293 cells was 
isolated using a Trizol reagent (ref. number 15596026, 
Invitrogen, United States), in accordance with the 
manufacturer’s procedure. A Superscript III kit (ref. 
number 18080200, Invivogen United States) was used 
for cDNA synthesis. The amount of cDNA encoding 
the NOD1 receptor was normalized with respect to the 
amount of GAPDH cDNA. Thirty-five PCR cycles were 
performed with the use of primers specific to the nu-
cleotide sequence of the cDNA sequence that encodes 
human NOD1 – NOD1-forw: ctt-ctg-gtc-act-cac-atc-
cgc-a, NOD1-rev: tgg-gca-tag-cac-agc-acg-aac. The 
primer annealing temperature was measured at 62оС.
Real-time measurement of bioluminescence intensity 
in the organism of BalB/С transgenic mice
The activity of the NF-kB factor in the organism of 
BalB/С transgenic mice containing the luciferase re-
porter gene in their genome, under expression control 
of the NF-kB-dependent promoter, was measured in 
real time on the basis of the bioluminescence intensity 
at intervals of 1, 3, and 5 h after PRR ligands (LPS or 
iE-DAP-C12) were introduced. Five minutes prior to 
obtaining the images, 1.5 mg of D-luciferin (Caliper 
Life Sciences) was injected into the mice. The biolu-
minescence intensity was determined on an IVIS Im-80 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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aging System 100 instrument (Xenogen Corp., United 
States).
Laboratory animals
Female transgenic mice of the BALB/c-Tg(NFkB-
RE-luc[Oslo])-Xen line (Caliper Life Sciences, United 
States) with a weight range of 18–20 g containing the 
reporter gene of firefly luciferase in their genome (from 
pGL3-Basic Vector, Promega, United States), under 
expression control of the NF-kB-dependent promoter 
consisting of three NF-kB-binding regions in the pro-
moter of the Igκ light chain gene, were used for the 
purposes of this experiment.
The mice were given free access to water and food. 
LPS (5 µg/mouse) and iE-DAP-C12 (200 µg/mouse) 
solutions were injected intramuscularly into the mice. 
RESULTS AND DISCUSSION
Comparison of the NF-kB-activating ability of NOD1 
receptor ligands under in vitro conditions
Dipeptide D-Glu-mDAP is known as the key sequence 
necessary and sufficient to inactivate the NOD1 recep-
tor upon the decomposition of gram-negative bacte-
ria and penetration of peptidoglycan fragments inside 
eukaryotic cells [10]. The participation of other amino 
acids and monosaccharides, the components of the 
structural molecules of peptidoglycan of gram-negative 
bacteria, in the recognition by the NOD1 receptor has 
yet to be described thoroughly (Fig. 1).
It thus follows that the study of the dependence of 
NOD1-mediated NF-kB-activating ability of various 
peptidoglycan fragments on their structure seems of 
importance.
In this context, we carried out a screening experi-
ment at a preliminary stage to select the cell model in 
which the expression of the NOD1 receptor by differ-
ent cell lines was determined. According to the RT-PCR 
data, expression of the NOD1 receptor was detected in 
both the HEK293 cell line (human embryonic kidney 
epithelial cells) and the HCT116 cell line (human colon 
carcinoma cells). TLR5 was also expressed in this cell 
line [11], whereas in Н1299 and A549 cell lines the ex-
pression of the NOD1 receptor could not be detected 
under the selected RT-PCR conditions (Fig. 2).
Considering that HEK293 line cells do not express 
TLR (their presence may result in the additional ac-
tivation of NF-kB when using NOD1 receptor ligands 
containing the impurities of TLR ligand molecules), this 
cell line served as a model for studying the ability of 
NOD1 receptor ligands possessing different structures 
to activate NF-kB.
Using  the  lentiviral  vector,  the  gene  of  the 
β-galactosidase reporter protein under the transcrip-
tional control of the NF-kB-dependent promoter and 
the marker of resistance to blasticidin S were intro-
duced into the genome of HEK293 cells. The principle 
of use of the resulting cell line is based on the ability of 
the NOD1 receptor after its interaction with specific 
ligands to activate the kinase cascade (RIP2, IKKα,β), 
which results  in the activation of the NF-kB factor, 
followed by its translocation into the nucleus, where 
this factor binds with the intrinsic regulatory element 
which controls the galactosidase gene. Hence, the activ-
Gram-negative  
bacterium
Cell wall of  
a gram-negative 
bacterium
Structure of the peptidoglycan 
of gram-negative bacterium
GlcNAc – MurNAc – GlcNAc – MurNAc












Fig. 1. NOD1 ligands in the 
peptidoglycan structure of Gram-
negative bacteria. 1 – D-Glu-
mDAP (iE-DAP), 2 – L-Ala-
D-Glu-L-mDAP (Tri-DAP), 3 
– MurNAc-L-Ala-D-Glu-L-mDAP 
(M-Tri-DAP), and 4 – GlcNAc-MurNAc-
L-Ala-D-Glu-L-mDAP (GM-Tri-DAP). 
GlcNAc – N-acetylglucosamine, 
MurNAc – N-Acetylmuramic acid, 
L-Ala – L-alanin, D-Glu – D-Glutamic 
acid, L-mDAP – L-meso-Diaminopimelic 
acid.RESEARCH ARTICLES
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ity of NF-kB in cells can be quantitatively determined 
on the basis of the staining reaction for galactosidase by 
registering the interaction between the NOD1 receptor 
and the intrinsic ligands.
In order to measure the NF-kB activity, NOD1 re-
ceptor ligands with a different structure were added to 
HEK293 line cells: dipeptide D-Glu-mDAP (iE-DAP), 
tripeptide L-Ala-D-Glu-L-mDAP (Tri-DAP), and 
tripeptide MurNAc-L-Ala-D-Glu-L-mDAP (M-Tri-
DAP) covalently bound with a monosaccharide. Fur-
thermore, in our work we used the covalently bound 
with disaccharide tripeptide GlcNAc-MurNAc-L-
Ala-D-Glu-L-mDAP (GM-Tri-DAP), prepared from 
N. meningitidis serogroup B and purified to mass spec-
trometrical purity using the earlier described method 
[10]. We additionally used a chemically synthesized 
molecule which contained the lauric acid fragment 
Lauroyl-γ-D-Glu-D-mDAP (iE-DAP-C12) capable of 
changing the physicochemical properties of this mol-
ecule, in addition to the minimal recognition sequence.
As can be seen in Fig. 3, a reliable increase in the NF-
kB-dependent activation of the β-galactosidase gene 
expression was attained only at maximum concentra-
tions (1–10 µg/ml) of the D-Glu-mDAP dipeptide add-
ed, whereas derivatives of this dipeptide with a higher 
molecular weight (Tri-DAP, M-Tri-DAP, and GM-
Tri-DAP) than those that can be found as components 
of peptidoglycan of gram-negative bacteria induced a 
reliable increase in NF-kB-dependent β-galactosidase 
gene expression at lower concentrations (from 
0.5 µg/ml). The maximum NOD1-mediated ability of 
NF-kD activation was shown by the chemically synthe-
sized molecule iE-DAP-C12. The minimum concentra-
tion of this molecule, which was capable of inducing the 
NF-kB-dependent activation of β-galactosidase gene 
expression, is equal to 20 ng/ml. Such a significant in-
crease in the NF-KB-activating ability (by a factor of 
approximately 1,000 as compared with D-Glu-mDAP) 
can be explained by the presence of the hydrophobic 
component of lauric acid, which is likely to facilitate 
the penetration of iE-DAP-C12 molecule through the 
plasma membrane and binding to the NOD1 receptor 
located in the cell cytoplasm.
 This experiment thus demonstrated that an in-
crease in the amino acid sequence in the structure of 
the NOD1 receptor ligand results in  a reliable increase 
in the NF-kB-activating ability of the molecule as com-
pared with the NF-kB-activating minimal sequence D-
Glu-mDAP, whereas the presence of monosaccharide 
residues within the ligand molecule does not further 
increase the activity.
 This phenomenon can be explained as follows. For 
an optimally efficient recognition by the NOD1 recep-
1  2  3  4
Fig.2. Expression levels of NOD1 receptor detected by 
RT-PCR with specific primers in 1 – human colon carcinoma 
cells HCT116, 2 – human embryonic kidney cells HEK293, 
3 – non-small cell lung carcinoma cells H1299, and 4 – hu-
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tor (in order to penetrate into the “pocket” of its ligand-
recognizing domain), a ligand molecule has to contain 
at least three covalently bound amino acids, whereas 
the additionally introduced saccharide molecules do 
not participate in the direct formation of the ligand-
receptor complex. Moreover, the NF-kB-activating 
ability of the NOD1 receptor ligand can be significantly 
increased (by a factor of approximately 1,000) by the 
enhanced hydrophobicity of the molecule, as a result of 
binding with a fatty acid residue.  In all likelihood, such 
a modification allows to speed up the process, ensuring 
the necessary ligand concentration near the receptor in 
the cytoplasm, because its penetration through the cell 
plasma membrane is made easier.
The iE-DAP-C12 ligand of the NOD1 receptor, 
which exhibited the highest activity, was selected for 
further studies.
Comparison of the NF-kB-activating ability of NOD1 
and TLR5 ligands in human colon carcinoma cells 
HCT116
In order to compare the NF-kB-activating ability of 
NOD1 and TLR5 ligands under in vitro conditions, the 
HCT116 cell line was selected as a model. This cell line 
expresses both the NOD1 receptor and TLR5, in which 
the bacterial flagellar protein flagellin serves as a lig-
and.
The NF-kB activity was measured on the basis of 
the expression of the luciferase gene, which was intro-
duced into the cell genome under the transcriptional 
control of the NF-kB-dependent element.
TNF-α was used as positive control of NF-kB activa-
tion. This cytokine stimulates NF-kB activation and in-
duces the expression of proinflammatory factors after 
its interaction with the intrinsic receptor.
The experimental results demonstrate (Fig. 4) that 
the most active NOD1 receptor–ligandiE-DAP-C12-
–has an effect on NF-kB that can be compared with 
that of flagellin, but in concentrations that are higher 
by a factor of 10–100 than those of flagellin. In light 
of the results of this experiment, a conclusion can be 
drawn that NOD1 receptor ligands activate NF-kB to a 
lesser degree than TLR5 ligand; at least for the delivery 
path that was used. This phenomenon can be explained 
by a number of reasons: the fact that the NOD1 recep-
tor ligands need to overcome additional barriers, such 
as the plasma membrane and the cytoplasmic space; 
a different affinity of TLR and NOD receptors to the 
intrinsic ligands; and the differences in the lower-lying 
signaling cascades, resulting in the activation of the 
transcriptional factor NF-kB.
The ability of NOD1 receptor ligands to induce spe-
cific immune responses upon a weaker NF-kB activa-
tion in eukaryotic cells as compared with TLR could 
be an indication that the level of NF-kB activity may 
determine the development of particular specific im-
mune responses and control their intensity.
The established ratio between the concentrations of 
NOD1 and TLR ligands which activate NF-kB was tak-
en into consideration to the same extent when carrying 
out the subsequent studies in in vivo conditions.
Studying the NF-kB-activating ability of the NOD1 
receptor ligand under in vivo conditions
It has been shown that the level of NF-kB activation 
may differ in different organs of laboratory animals 
into which TLR ligands has been injected [12, 13]. How-
ever, to date there has been no data that clearly shows 
the ability of the ligands of other PRR–NOD receptors 
to induce NF-kB activation under in vivo conditions. 
We investigated this question by determining the ma-
jor activation parameters (the kinetics and intensity of 
activation in different organs) upon introduction of the 













































Fig. 4. NF-kB activity in HCT116 
expressing NOD1 and TLR5. 
■ – cells treated with TLR5 ligand – 
flagellin;  ■– cells treated with NOD1 
ligand – iE-DAP-C12; ■ – control 
intact cells; ■ – cells treated with 
TNF-α (concentration 10 ng/ml). 
NF-kB-dependent luciferase activity 
was detected by spectrophotomet-
ric measurement of bioluminescence 
after addition of specific substrate - 
luciferin. Y-direction – luminescence 
intensity units (CPS).RESEARCH ARTICLES
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the highest activity in in vitro experiments. Further-
more, we compared the NF-kB-activating abilities of 
NOD ligands and those of TLR4, the thoroughly stud-
ied Toll-like receptor, under in vivo conditions upon 
intramuscular injection.
To this end, we used BalB/C transgenic mice with 
the luciferase reporter gene incorporated into their ge-
nome, under the control of a NF-kB-depending pro-
moter. Such a system allows to measure the degree of 
NF-kB activation in different mouse organs, on the 
basis of luminescent glowing upon the introduction of 
PRR ligands [14].
In order to compare the parameters of the NF-kB 
activation that is observed upon the introduction of iE-
DAP-C12, we selected LPS, the ligand of the Toll-like 
receptor that has been best studied under in vivo con-
ditions [13, 15, 16].
The amounts of NOD1 and TLR4 ligands were select-
ed based on the data on the NF-kB-activating ability of 
these ligands under in vitro conditions (200 µg/mouse 
and 5 µg/mouse, respectively).
It was demonstrated (Fig. 5) that upon the intra-
muscular introduction of iE-DAP-C12, the highest 
relative and absolute inductions of NF-kB activation 
(over 12 times) take place in the liver. Moreover, in 
the liver and the small intestine the highest degree of 
NF-kB activation is attained 5 h after the introduction 
of a ligand, whereas a decrease in the level of NF-kB 
activation was observed at that time in other organs. 
In three out of nine organs of laboratory animals (kid-
neys, heart, and small intestine), the introduction of 
the NOD1 ligand resulted in a minimum increase in the 
NF-kB activation, as compared with the level of NF-kB 
activation in the control group.
At the final stage, we compared the levels of NF-kB 
activation in different organs of mice which received 
intramuscularly iE-DAP-C12 and LPS 3 h after the in-
troduction of the ligands (maximum NF-kB activation 
point).
As can be seen in Figs. 6a and 6b, the introduction of 
LPS results in a stronger NF-kB activation in a number 
of organs (liver, spleen, uterus, and small intestine), 
when compared with iE-DAP-C12. In the large intes-
tine, lungs, and urinary bladder, the introduction of 
NOD1 and TLR4 ligands induced a comparable level of 
NF-kB activation. In other organs such as kidneys and 
the heart, no reliable increase in the level of NF-kB ac-
tivation was observed as a response to the introduction 
of both iE-DAP-C12 and LPS.
Thus, according to the results of the study of the 
ability of NOD1 ligands to activate NF-kB under  in 
vivo conditions, a conclusion can be drawn that the in-
tensity and kinetics of NF-kB activation in response 
to the introduction of these ligands differ in different 
mouse organs. Furthermore, differences in the inten-
sity of NF-kB activation in mouse organs after the in-
troduction of NOD1 and TLR4 ligands in the selected 
concentrations were detected.
 After summarizing the data obtained, a conclusion 
can be drawn that the NF-kB factor activation induced 
by the interaction between the NOD1 receptor with 
intrinsic ligands differs from that upon stimulation of 
TLR representatives (kinetics and intensity of activa-
tion) in the same organ, which could be essential for 
the development of the subsequent immune responses. 
Moreover, the demonstrated tissue- and organ-specif-
icity of NF-kB upon the introduction of Toll- or NOD 
receptor ligands into the organism of an animal may 
lead to the development of different local immune re-
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Fig. 5. NF-kB activity in mouse organ homogenates 1,3,5 h after iE-DAP-C12 administration. Samples were normalized 
with respect to concentration of total protein (10mg/ml). ■ –NF-kB activity in organs of control intact mice 3 h after 
PBS injection. ■ – NF-kB activity in organs of mice 1 h after iE-DAP-C12 injection (200 µg/animal). ■ – NF-kB activity in 
organs of mice 3 h after iE-DAP-C12 injection (200 µg/animal). ■ – NF-kB activity in organs of mice 5 h after iE-DAP-C12 
injection (200 µg/animal). NF-kB-dependent luciferase activity was detected by spectrophotometric measurement of 
bioluminescence after addition of specific substrate - luciferin. Y-direction – luminescence intensity units (CPS).84 | ACTA NATURAE |  VOL. 3  № 1 (8)  2011
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in the spectra of secreted cytokines may be observed). 
The development of some immune responses can be ac-
counted for by the distinctions in differentiation and 
cell types representing a tissue in which the induction 
of NF-kB activation took place.
The ability of NOD1 receptor ligands to activate the 
NF-kB factor under in vivo conditions can be used for 
creating new molecular adjuvants which are charac-
terized by a lower reactogenecity in comparison with 
some TLR ligands (e.g., LPS). Such adjuvants could 
be used together with vaccine antigens for protection 
against different pathogens, including intracellular 
ones. In order to bolster this hypothesis further, a de-
tailed analysis of the individual immune responses 
that are initiated by the activation of NOD receptors 
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Fig.6.a - Real-time in vivo imaging of NF-kB activity in mouse organism after administration of iE-DAP-C12 (left) and 
LPS of E. coli (right). Red arrows point to the maximal bioluminescence intensity detected in liver after PRR ligands 
exposure. b - NF-kB activity in mouse organ homogenates 3 h after iE-DAP-C12 and LPS administration. Samples were 
normalized with respect to the concentration of total protein (10 mg/ml). ■ – NF-kB activity in organs of control intact 
mice 3 h after PBS injection. ■ – NF-kB activity in organs of mice 3 h after iE-DAP-C12 injection (200 µg/animal). ■ – NF-
kB activity in organs of mice 3 h after LPS injection (5 µg /animal). NF-kB-dependent luciferase activity was detected by 
spectrophotometric measurement of bioluminescence after addition of the specific substrate - luciferin. Y-axis – lumines-
cence intensity units (CPS).
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